Durham – September 15, 2026 -- Seismic Pharmaceuticals has commenced a global Phase 3 trial of Istaroxime, aiming to deliver the first-ever approved drug for cardiogenic shock, a condition with no currently FDA-approved treatments.

Trial to enroll 600 patients across three continents

The study, named Rescue HF CS, will recruit approximately 600 patients at clinical sites in the United States, Europe and South America. It builds on four completed Phase 2 trials in which more than 340 patients received Istaroxime.

Washington – – September 15, 2026 -- Clearsight Advisors served as exclusive sell-side advisor to Ambit RD, Inc. on its acquisition by Danforth Health, Inc., a portfolio company of Avesi Partners, in a deal announced by the firms.

Paramus, N.J. – – September 15, 2026 -- A prespecified secondary analysis of the landmark FIBRES trial found that Octapharma's fibryga (fibrinogen [human]) cut 24-hour allogeneic blood-product transfusion requirements by 19% versus cryoprecipitate in two overlapping patient subgroups, according to findings published in the Journal of Cardiothoracic and Vascular Anesthesia.

Los Angeles – September 15, 2026 -- Partillion Bioscience has secured a two-year, $2.1 million NIH Small Business Innovation Research (SBIR) award to scale its Cell-Cell-seq technology toward datasets of up to one million cell pairs. The grant, awarded by the National Institute of General Medical Sciences (NIGMS) under Award Number R44GM165220, is Partillion's 10th SBIR grant and brings the company's total non-dilutive federal funding past $8 million, roughly matching its private investment to date without additional equity dilution.

Barcelona, Spain – September 15, 2026 -- Altesa BioSciences reported that its investigational oral antiviral vapendavir significantly reduced two key inflammatory biomarkers, IP-10/CXCL10 and GM-CSF, in COPD patients experimentally infected with rhinovirus, according to data presented at the European Respiratory Society (ERS) International Congress 2026.

Jupiter, Florida – September 15, 2026 -- Cytonics Corporation has closed a financing campaign generating $4.8 million in gross proceeds, pushing its total capital raised to $47 million and expanding its investor base to approximately 8,000 shareholders.

New York City – September 15, 2026 -- Mice fed 30 percent fewer calories than their normal intake showed reduced levels of DNA mutations across multiple tissues, according to a study published September 9 in Cell by researchers at NYU Langone Health and University Hospitals Cleveland.

Monroe, Ohio – September 15, 2026 -- CSafe, a provider of temperature-controlled shipping solutions for the life sciences industry, has appointed Will Romanowicz as Chief Legal Officer, effective September 9, 2026.

Romanowicz Brings Decade-Plus of Regulated-Industry Legal Experience

Romanowicz joins with more than ten years of legal, governance, and commercial leadership across FDA-regulated sectors, including biotech, agribusiness, SaaS, food & beverage, and supplements. He has worked with both large global public companies and late-stage startups.

South San Francisco, Calif. – September 15, 2026 -- Apeximmune Therapeutics said a peer-reviewed study published in Nature independently validates PLA2G2D as a novel immune checkpoint capable of overcoming resistance to anti-PD-1 cancer therapies, with the company's lead antibody AI-306 targeting an IND filing in the second quarter of 2027.

The Woodlands, Texas – September 15, 2026 -- Cellipont Bioservices and Xiogenix have published a joint white paper showing that Xiogenix's ARES X20+ automated fill-finish platform maintained formulation volume accuracy of 98.2% at small scale and 103.6% at large scale across an approximately 17-fold increase in process scale.

The paper, titled "Scaling Cell and Gene Therapy Manufacturing with Automated Formulation and Fill-Finish," details Cellipont's evaluation of the platform across small and large-scale cell therapy manufacturing workflows.